Q2 2025 Earnings Call Transcript August 19, 2025 Operator: Hello, and welcome to Evaxion’s Second Quarter 2025 Conference Call. [Operator Instructions] I would now like to turn the conference over to ...

MSD expects to see an additional $200m layered onto its costs this year as a result of President Trump's tariffs, ahead of any pharma-specific levy.

Armed with positive results in two phase 3 trials, MSD is poised to be the first to file for approval of an oral PCSK9 drug to lower cholesterol ...

A groundbreaking study reveals ctDNA testing outperforms traditional imaging in predicting outcomes for large B-cell lymphoma ...

If approved, Signatera could help physicians to monitor molecular markers of bladder cancer relapse, allowing them to ...

The MMR IHC Panel PharmaDx (Dako Omnis) is used to identify loss of function in mismatch repair proteins and inform the treatment of colorectal cancer patients.

Reviewers winnowed an initial 27 assays to a group of nine that were evaluated using NCI sample sets, ultimately choosing ClearNote's Avantect and Guardant's Shield.